Cat. No. 4368
Alternative Names: PF 02341066, PF 2341066
Chemical Name: 3-[(1R)-1-(2,6-Dichloro-3-fluorophe
Biological ActivityPotent inhibitor of c-MET and anaplastic lymphoma kinase (ALK) (cell IC50 values are 8.0 and 20 nM respectively). Selective for c-MET and ALK against >120 different kinases. Displays antitumor efficacy in multiple tumor models; inhibits c-MET-dependent proliferation, migration and invasion of human tumor cells in vitro. Orally bioavailable.
Licensing InformationSold for research purposes under agreement from Pfizer Inc.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Certificate of Analysis / Safety Data Sheet
Christensen et al (2007) Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Mol.Cancer Ther. 6 3314. PMID: 18089725.
Zou et al (2007) An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms. Cancer Res. 67 4408. PMID: 17483355.
Cui et al (2011) Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK). J.Med.Chem. 54 6342. PMID: 21812414.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
View Related Products by Product Action
Keywords: Crizotinib, supplier, c-MET, alk, anaplastic, lymphoma, kinases, antitumor, selective, potent, PF2341066, PF02341066, Tocris Bioscience, ALK Inhibitors
Find multiple products by catalog number
New Products in this Area
Potent VEGFR inhibitor; also aromatase inhibitorPF 06463922
High affinity and selective ALK and ROS1 inhibitor6bK
Insulin degrading enzyme (IDE) inhibitor
March 14 - 16, 2016
New Orleans, LA, USA